JSJoseph Sexton

Joseph Sexton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph Sexton has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial

    by Johanna E. Gehin, Rolf A. Klaasen, Eirik K. Kristianslund, Ingrid Jyssum, Joseph Sexton, David J. Warren, Daniel Aletaha, Espen A. Haavardsholm, Guro L. Goll, Silje W. Syversen, et al.

    Objectives: To determine how certolizumab pegol (CZP) dose and dose adjustments influence CZP plasma trough levels to facilitate therapeutic drug monitoring of CZP. Methods: The effect of CZP dose and dose adjustments on CZP plasma trough levels was evaluated post hoc using longitudinal data from a 52-week randomized phase III trial (RAPID 1) and its open-label extension trial. Patients with active rheumatoid arthritis treated with methotrexate for ≥6 months were randomized to CZP 200 mg, 400 mg, or placebo every other week (EOW). Patients in the extension trial were initially treated with CZP 400 mg EOW, then reduced to 200 mg EOW after ≥6 months. Results: Of 982 randomized patients, 846 patients entered the open-label extension trial. Median (interquartile range) plasma CZP concentrations after 12 weeks of treatment were 21.3 mg/L (14.7, 27.7) in the 200-mg group and 38.3 mg/L (29.2, 63.8) in the 400-mg group and increased from 18.3 (12.4, 26.5) to 43.4 (26.8, 63.3) mg/L after dose escalation from 200 to 400 mg EOW. Following CZP dose reduction from 400 mg to 200 mg, median CZP levels decreased from 36.1 (24.9, 49.0) to 17.2 (11.5, 23.1) mg/L. Conclusions: CZP plasma concentrations were influenced by both dose and dose adjustment in a predictable manner, with median plasma levels twice as high in the 400-mg group than in the 200-mg group, with a 2-fold increase after the dose increase from 200 to 400 mg. This facilitates the development of algorithms for therapeutic drug monitoring of CZP.

  • Open Access

    Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial

    by Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, Ingrid Jyssum, Joseph Sexton, David John Warren, Daniel Aletaha, Espen Andre Haavardsholm, Silje Watterdal Syversen, Guro Løvik Goll, et al.

    Objectives The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. Methods Associations between serum adalimumab trough levels and disease activity were examined using longitudinal data from a 48-week randomised phase III trial including patients with tumour necrosis factor inhibitor-naïve rheumatoid arthritis with active disease starting adalimumab treatment. Disease activity was classified according to 28-joint Disease Activity Score (DAS28)-erythrocyte sedimentation rate and C reactive protein (CRP) levels. Results Adalimumab trough levels were recorded longitudinally for 336, 330 and 302 patients at weeks 12, 24 and 48, respectively. All patients received concomitant methotrexate. Median adalimumab trough levels were 6.4 mg/L (IQR 3.4–9.5) at week 12, 7.5 mg/L (IQR 3.5–10.9) at week 24 and 7.6 mg/L (IQR 3.6–12.0) at week 48. In serial serum samples from weeks 12, 24 and 48, trough levels ≥3.9 mg/L were associated with DAS28 remission (OR 3.88 (95% CI 1.80, 8.38), pConclusion Adalimumab trough levels above 4.0 mg/L were associated with remission/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring of adalimumab therapy.


  • Open Access

    Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

    by Karen Holten, Nina Paulshus Sundlisæter, Joseph Sexton, Kaja E Kjørholt, Lena Bugge Nordberg, Ellen Moholt, Till Uhlig, Désirée van der Heijde, Daniel H Solomon, Espen A Haavardsholm, et al.

    Objectives To explore the agreement between patient-reported flare status and clinically significant flare status in patients with rheumatoid arthritis (RA) in sustained remission. Method Patients with RA in remission for ≥12 months on stable treatment were included in the ARCTIC REWIND tapering trials and pooled 12-month data used in current analyses. Patient-reported flare status was assessed according to the Outcome Measures in Rheumatology flare questionnaire; ‘Are you having a flare of your RA at this time?’ (yes/no). A clinically significant flare was defined as a combination of Disease Activity Score (DAS) >1.6, increase in DAS of ≥0.6 and 2 swollen joints, or the rheumatologist and patient agreed that a clinically significant flare had occurred. Agreement coefficient, sensitivity, specificity and predictive values of patient-reported flare status with regard to clinically significant flare status were determined. Results Of 248 patients, 64% were women, age 56.1 (11.8) years, disease duration 4.1 (2.8–7.4) years, DAS 0.8 (0.3). 35% of patients reported a flare at least once, clinically significant flares were recorded in 21%. 48/53 clinically significant flares (91%) led to an intensification of disease-modifying antirheumatic drugss. In 621/682 (91%) visits, patient-reported and clinically significant flare status were in agreement, agreement coefficient 0.89. Sensitivity and specificity were both 91%, positive predictive value of patient-reported flare status 46% and negative predictive value 99%. Conclusion Among patients in sustained remission, patient-reported flare status was accurate in ruling out a clinically significant flare. About half of the patient-reported flares were assessed to be clinically significant. These findings support a potential for using patient-reported flare status in remote monitoring of patients with RA in sustained remission.


  • Open Access

    Associations between pain sensitization and measures of physical function in people with hand osteoarthritis: Results from the Nor-Hand study

    by Marthe Gløersen, Pernille Steen Pettersen, Tuhina Neogi, Joseph Sexton, Tore K. Kvien, Hilde Berner Hammer, Ida K. Haugen


  • Open Access

    POS0088 WORK PRODUCTIVITY IN GOUT – RESULTS FROM THE NOR-GOUT LONGITUDINAL 2-YEAR TREAT-TO-TARGET STUDY

    by T. Uhlig, L. F. Karoliussen, J. Sexton, S. Aarrestad Provan, T. K. Kvien, E. A. Haavardsholm, H. B. Hammer

    Background Gout causes pain and reduced health related quality of life. There are no longitudinal studies on work productivity in patients who are being treated-to target for their serum urate in clinical practice. Objectives We examined whether work productivity in gout patients changed over 2 years after intensive treatment with ULT, and if disease related factors could predict changes in work productivity. Methods Patients with crystal-proven gout and a recent gout flare and increased serum urate (sUA) level (>360 μmol/L) were consecutively included in the NOR-Gout observational study [1]. They were treated to target with an educational intervention by a study nurse and escalating urate lowering medication (allopurinol or febuxostat) with frequent control visits to achieve low serum urate at target. Work productivity and activity impairment were assessed using the Work Productivity Activity Index (WPAI) questionnaire at baseline, after 3 months, 6 months, 1 and 2 years. The WPAI consists of six questions to determine employment status during the last 7 days: hours missed from work due to the disease; hours missed from work for other reasons; hours worked, the degree to which the disease affected work productivity while at work; and the degree to which the disease affected activities outside of work. Four scores were derived: percentage of missed work (absenteeism), percentage of impaired productivity while at work (presenteeism), overall work impairment that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Greater scores indicate greater impairment. Questions related to absenteeism and presenteeism were applicable only for patients who were working. Other assessments included clinical, demographic and lifestyle variables, and questionnaires, comorbidities from the Self-Administered Comorbidity Questionnaire, pain, physical function from the Health Assessment Questionnaire (HAQ), SF-36 physical and mental components, self-efficacy, and the Beliefs about Medicines Questionnaire (BMQ) with subscales of beliefs in harm, overuse, necessity, and concerns about medication. Descriptive statistics used ANOVA, and linear regression model after logarithmic transformation of the 4 WPAI outcomes. Final regression models were also adjusted for baseline, age, gender, disease duration and comorbidities. Results Patients were predominantly male (95%) with mean age 56.4 years (SD 13.7 years) and disease duration almost 8 years, 17% had subcutaneous tophi. At baseline 64.4 % were working, 64.0% at year one and 61.3% after 2 years. sUA was at target Conclusion In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged over 2 years and at 1 year and were predicted by comorbidities and patient concerns about medication. Reference [1]Uhlig T et al. RMD Open 2021;7(1):e001628 Acknowledgements: NIL. Disclosure of Interests Till Uhlig Consultant of: Grünenthal, Novartis, Lars Fridtjof Karoliussen: None declared, Joe Sexton: None declared, Sella Aarrestad Provan Consultant of: Böhringer Ingelheim, Tore K. Kvien Consultant of: AbbVie, MSD, UCB, Hospira/Pfizer, BMS, Sanofi, Celltrion, Sandoz, Amgen, and Galapagos, Espen A Haavardsholm Consultant of: Pfizer, UCB, Eli Lilly, Celgene, Janssen-Cilag, AbbVie and Gilead, Hilde Berner Hammer Consultant of: AbbVie, Lilly, UCB and Novartis.

  • Open Access

    Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit

    by Anne Grete Semb, Silvia Rollefstad, Eirik Ikdahl, Grunde Wibetoe, Joseph Sexton, Cindy Crowson, Piet van Riel, George Kitas, Ian Graham, Solbritt Rantapää-Dahlqvist, et al.

    Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014–2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (pConclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .


  • Open Access

    Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)

    by Silje W Syversen, Guro L Goll, Kristin K Jørgensen, Inge C Olsen, Øystein Sandanger, Johanna E Gehin, David J Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, et al.

    Background: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune mediated inflammatory diseases. Still, many patients do not respond sufficiently to therapy or lose efficacy over time. The large interindividual variation in serum drug concentrations on standard doses and the development of anti-drug antibodies are thought to be major reasons for treatment failures. Therapeutic drug monitoring (TDM), an individualised treatment strategy based on systematic assessments of serum drug concentrations, has been proposed as a clinical tool to optimise efficacy of INX treatment. TDM seems reasonable both from a clinical and an economical point of view, but the effectiveness of this treatment strategy has not yet been demonstrated in randomised clinical trials. The NORwegian DRUg Monitoring study (NOR-DRUM) aims to assess the effectiveness of TDM, both with regard to the achievement of remission in patients starting INX treatment (part A) as well as to maintain disease control in patients on INX treatment (part B). Methods: The NOR-DRUM study is a randomised, open, controlled, parallel-group, comparative, multi-centre, national, superiority, phase IV study with two separate parts, NOR-DRUM A and NOR-DRUM B. Patients with rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, ulcerative colitis, Crohn’s disease and psoriasis are included. In both study parts participants are randomised 1:1 to either TDM of infliximab (intervention group) or to standard treatment with infliximab without knowledge of drug levels or ADAb status (control group). NOR-DRUM A will include 400 patients starting INX therapy. The primary outcome is remission at 30 weeks. In NOR-DRUM B, 450 patients on maintenance treatment with INX will be included. The primary endpoint is occurrence of disease worsening during the 52-week study period. Discussion: As the first trial to assess the effectiveness, safety and cost-effectiveness of TDM in patients receiving TNFi for a range of immune mediated inflammatory diseases, we hope that the NOR-DRUM study will contribute to the advancement of evidence based personalised treatment with biological medicines. Trial registration: Clinicaltrials.gov, NCT03074656. Registered on 090317.


  • Open Access

    Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study

    by Lene Terslev, Mikkel Østergaard, Joe Sexton, Hilde Berner Hammer

    To explore to what extent synovial hypertrophy in joints without Doppler activity is a sign of active disease, we investigated the sensitivity to change of synovial hypertrophy without Doppler activity during biological disease-modifying antirheumatic drug (bDMARD) treatment in rheumatoid arthritis (RA) patients. RA patients initiating or switching bDMARD treatment had ultrasound (US) performed on 36 joints at baseline, and at 3 and 6 months. Synovial hypertrophy by grayscale US and Doppler activity were graded separately from 0 to 3 at the joint level for all time points. Changes in synovial hypertrophy in joints without Doppler activity during treatment were assessed and compared with changes in synovial hypertrophy in joints with Doppler activity. We included 151 patients (82.8% women, 80.1% seropositive for anticyclic citrullinated peptide) with a mean ± standard deviation age of 51.4 ± 13.2 years, a disease duration of 9.9 ± 7.9 years, and baseline Disease Activity Score 28-joint count C-reactive peptide (DAS28-CRP) of 4.14 ± 1.32. At baseline, 44.8% of all joints examined (n = 5225) had synovial hypertrophy ≥ 1 and 50.7% of these had synovial hypertrophy without Doppler activity. The improvement in synovial hypertrophy was similar in joints with and without Doppler activity but, when adjusting for the baseline score of synovial hypertrophy, joints with synovial hypertrophy without Doppler had a higher tendency towards a decrease than joints with synovial hypertrophy with Doppler activity independent of grade (3 months: p < 0.0001; 6 months: p = 0.0003). Joints with synovial hypertrophy without Doppler activity improve during treatment, independent of the grade. Thus, SH without Doppler activity is not a sign of inactive disease. These findings indicate that joints with synovial hypertrophy without Doppler activity should also be taken in to account when assessing disease activity by US.


  • Subroutine based detection of APT malware

    by Joseph Sexton, Curtis Storlie, Blake Anderson